Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 380

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer

Open access
Parikh, Aparna R., Van Seventer, Emily E., Siravegna, Giulia, Hartwig, Anna V., Jaimovich, Ariel, He, Yupeng, Kanter, Katie, Fish, Madeleine G., Fosbenner, Kathryn D., Miao, Benchun, Phillips, Susannah, Carmichael, John H., Sharma, Nihaarika, Jarnagin, Joy, Baiev, Islam, Shah, Yojan S., Fetter, Isobel J., Shahzade, Heather A., Allen, Jill N., Blaszkowsky, Lawrence S., Clark, Jeffrey W., Dubois, Jon S., Franses, Joseph W., Giantonio, Bruce J., Goyal, Lipika, Klempner, Samuel J., Nipp, Ryan D., Roeland, Eric J., Ryan, David P., Weekes, Colin D., Wo, Jennifer Y., Hong, Theodore S., Bordeianou, Liliana, Ferrone, Cristina R., Qadan, Motaz, Kunitake, Hiroko, Berger, David, Ricciardi, Rocco, Cusack, James C., Raymond, Victoria M., Talasaz, AmirAli, Boland, Genevieve M., Corcoran, Ryan B. · 2021 · Clinical Cancer Research

Abstract

Purpose: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery can identify patients with minimal residual disease (MRD) who will ultimately recur. Most ctDNA MRD assays require tumor sequencing to identify tumor-derived mutations to facilitate ctDNA detection, requiring tumor and blood. We evaluated a plasma-only ctDNA assay integrating genomic and epigenomic cancer signatures to enable tumor-uninformed MRD detection. Experimental Design: A total of 252 prospective serial plasma specimens from 103 patients with colorectal cancer undergoing curative-intent surgery were analyzed and correlated with recurrence. Results: Of 103 patients, 84 [stage I (9.5%), II (23.8%), III (47.6%), IV (19%)] had evaluable plasma drawn after completion of definitive therapy, defined as surgery only (n = 39) or completion of adjuvant therapy (n = 45). In “landmark” plasma drawn 1-month (median, 31.5 days) after definitive therapy and >1 year follow-up, 15 patients had detectable ctDNA, and all 15 recurred [positive predictive value (PPV), 100%; HR, 11.28 (P < 0.0001)]. Of 49 patients without detectable ctDNA at the landmark timepoint, 12 (24.5%) recurred. Landmark recurrence sensitivity and specificity were 55.6% and 100%. Incorporating serial longitudinal and surveillance (drawn within 4 months of recurrence) samples, sensitivity improved to 69% and 91%. Integrating epigenomic signatures increased sensitivity by 25%–36% versus genomic alterations alone. Notably, standard serum carcinoembryonic antigen levels did not predict recurrence [HR, 1.84 (P = 0.18); PPV = 53.9%]. Conclusions: Plasma-only MRD detection demonstrated favorable sensitivity and specificity for recurrence, comparable with tumor-informed approaches. Integrating analysis of epigenomic and genomic alterations enhanced sensitivity. These findings support the potential clinical utility of plasma-only ctDNA MRD detection. See related commentary by Bent and Kopetz, p. 5449

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-21-0410

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 380

Metadata

Authors
Parikh, A. R., Van Seventer, E. E., Siravegna, G., Hartwig, A. V., Jaimovich, A., He, Y., Kanter, K., Fish, M. G., Fosbenner, K. D., Miao, B., Phillips, S., Carmichael, J. H., Sharma, N., Jarnagin, J., Baiev, I., Shah, Y. S., Fetter, I. J., Shahzade, H. A., Allen, J. N., Blaszkowsky, L. S., Clark, J. W., Dubois, J. S., Franses, J. W., Giantonio, B. J., Goyal, L., Klempner, S. J., Nipp, R. D., Roeland, E. J., Ryan, D. P., Weekes, C. D., Wo, J. Y., Hong, T. S., Bordeianou, L., Ferrone, C. R., Qadan, M., Kunitake, H., Berger, D., Ricciardi, R., Cusack, J. C., Raymond, V. M., Talasaz, A., Boland, G. M., & Corcoran, R. B.
Venue
Clinical Cancer Research
Published
2021-04-29
Volume
27
Issue
20
Pages
5586-5594
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3159598242
Cited by
380
References
26
FWCI
20.29
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-21-0410
The paper
Parikh, A. R., Van Seventer, E. E., Siravegna, G., Hartwig, A. V., Jaimovich, A., He, Y., Kanter, K., Fish, M. G., Fosbenner, K. D., Miao, B., Phillips, S., Carmichael, J. H., Sharma, N., Jarnagin, J., Baiev, I., Shah, Y. S., Fetter, I. J., Shahzade, H. A., Allen, J. N., . . . Corcoran, R. B. (2021). Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-0410

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.